The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1485-1495

  Horak, Jiri ^a   White, Jeff ^b   Harris, Adrian L ^c   Verrill, Mark ^d   Carmichael, James ^e,f   Holt, Alison ^f   Cantarini, Mireille ^f   MacPherson, Merran ^f   Swaisland, Alan ^f   Swaisland, Helen ^f   Twelves, Chris ^g  

^a CHARLES UNIVERSITY   (Czech Republic)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^f ASTRAZENECA   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cirrhosis; Gefitinib; Hepatic impairment; Liver metastases; Pharmacokinetics

Indexed keywords

GEFITINIB;

ACNE; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST CARCINOMA; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG HALF LIFE; DRUG TOLERABILITY; DRY SKIN; ECZEMA; EYE PAIN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER METASTASIS; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PEPTIC ULCER; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SOMNOLENCE; STEADY STATE; STOMATITIS; TASTE PERVERSION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 82455175183     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1611-2     Document Type: Article

References (33)

1. MG Donelli M Zucchetti E Munzone M D'Incalci A Crosignani 1998 Pharmacokinetics of anticancer agents in patients with impaired liver function Eur J Cancer 34 33 46 9624235 10.1016/S0959-8049(97)00340-7 1:CAS:528: DyaK1cXitFeks78%3D (Pubitemid 28123378)
2. EA Sotaniemi O Niemelä L Risteli F Stenbäck RO Pelkonen JT Lahtela J Risteli 1986 Fibrotic process and drug metabolism in alcoholic liver disease Clin Pharmacol Ther 40 46 55 3720178 10.1038/clpt.1986.138 1:STN:280:DyaL283ks1Sgtw%3D%3D (Pubitemid 16057981)
3. I Robieux R Sorio E Borsatti R Cannizzaro V Vitali P Aita A Freschi E Galligioni S Monfardini 1996 Pharmacokinetics of vinorelbine in patients with liver metastases Clin Pharmacol Ther 59 32 40 8549031 10.1016/S0009-9236(96) 90021-1 1:CAS:528:DyaK28XhsFylsbo%3D (Pubitemid 26046769)
4. JM Kolesar 2000 Docetaxel in hepatic impairment J Oncol Pharm Prac 6 43 49 1:CAS:528:DC%2BD3cXlvFeku7s%3D
5. SJ Clarke LP Rivory 1999 Clinical pharmacokinetics of docetaxel Clin Pharmacokinet 36 99 114 10092957 10.2165/00003088-199936020-00002 1:CAS:528:DyaK1MXitFCntL0%3D (Pubitemid 29121684)
6. Y Chao WK Chan MJ Birkhofer OY Hu SS Wang YS Huang M Liu J Whang-Peng KH Chi WY Lui SD Lee 1998 Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients Br J Cancer 78 34 39 9662247 10.1038/bjc.1998.438 1:CAS:528:DyaK1cXksVynt7o%3D (Pubitemid 28276766)
7. US Department of Health and Human Services Food and Drug Administration (2003) Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis and impact on dosing and labeling. US food and drug administration. http://www.fda.gov/cber/gdlns/imphep.pdf. Accessed 9 Jan 2009
8. European Medicines Agency. Committee for medicinal products for human use (2005) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. European medicines agency. http://www.emea.europa.eu/pdfs/human/ewp/233902en.pdf. Accessed 8 Jan 2009
9. Twelves CJ (2006) Special populations and interaction studies. In: Eisenhauser EA, Twelves C, Buyse M (eds) Phase I cancer clinical trials: a practical guide. Oxford University Press, Oxford, pp 95-137
10. C Twelves R Glynne-Jones J Cassidy J Schüller T Goggin B Roos L Banken M Utoh E Weidekamm B Reigner 1999 Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites Clin Cancer Res 5 1696 1702 10430071 1:CAS:528:DyaK1MXltVCqtrw%3D (Pubitemid 29334448)
11. N Thatcher A Chang P Parikh J Rodrigues Pereira T Ciuleanu J von Pawel S Thongprasert EH Tan K Pemberton V Archer K Carroll 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer) Lancet 366 1527 1537 16257339 10.1016/S0140-6736(05)67625-8 1:CAS:528:DC%2BD2MXhtFKhsbfP (Pubitemid 41540110)
12. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa J-Y Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova R-P Dong J Baselga 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237 2246 12748244 10.1200/JCO.2003.10.038 1:CAS:528:DC%2BD2cXpsVGqu7w%3D (Pubitemid 46621858)
13. MG Kris RB Natale RS Herbst TJ Lynch Jr 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149 2158 14570950 10.1001/jama.290.16.2149 1:CAS:528:DC%2BD3sXosVOnsbo%3D (Pubitemid 37432975)
14. TS Mok Y-L Wu S Thomgprasert C-H Yang D-T Chu N Saijo P Sunpaweravong B Han B Margono Y Ichinose Y Nishiwaki Y Ohe J-J Yang B Chewaskulyong H Jiang EL Duffield CL Watkins AA Armour M Fukuoka 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
15. D McKillop M Hutchison EA Partridge N Bushby CM Cooper JA Clarkson-Jones 2004 Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor: in rat, dog and man Xenobiotica 34 917 934 15764411 10.1080/00498250400009171 1:CAS:528:DC%2BD2cXhtFGmu77I (Pubitemid 39648170)
16. D McKillop AD McCormick A Millar GS Miles PJ Phillips M Hutchison 2005 Cytochrome P450-dependent metabolism of gefitinib Xenobiotica 35 39 50 15788367 10.1080/00498250400026464 1:CAS:528:DC%2BD2MXisVyis7k%3D (Pubitemid 40459216)
17. 14C]- ZD1839 ('Iressa') in healthy male volunteers. Poster presented at ESMO, Nice
18. RN Pugh IM Murray-Lyon JL Dawson MC Pietroni R Williams 1973 Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 646 649 4541913 10.1002/bjs.1800600817 1:STN:280:DyaE3s3jsVWqsw%3D%3D
19. HK Jones LE Stafford HC Swaisland R Payne 2002 A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials J Pharm Biomed Anal 29 221 228 12062681 10.1016/S0731-7085(02)00014-6 1:CAS:528:DC%2BD38Xktlynu7c%3D (Pubitemid 34621284)
20. H Swaisland A Laight L Stafford H Jones C Morris A Dane R Yates 2001 Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers Clin Pharmacokinet 40 297 306 11368294 10.2165/00003088-200140040-00005 1:CAS:528:DC%2BD3MXktF2gur8%3D (Pubitemid 32458155)
21. HC Swaisland RP Smith A Laight DJ Kerr M Ranson CH Wilder-Smith T Duvauchelle 2005 Single-dose clinical pharmacokinetic studies of gefitinib Clin Pharmacokinet 44 1165 1177 16231967 10.2165/00003088-200544110-00004 1:CAS:528:DC%2BD2MXhtlSgtbrJ (Pubitemid 41483701)
22. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott Williams and Wilkins, Baltimore
23. K Nakagawa T Tamura S Negoro S Kudoh N Yamamoto N Yamamoto K Takeda H Swaisland I Nakatani M Hirose R-P Dong M Fukuoka 2003 Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 14 922 930 12796031 10.1093/annonc/mdg250 1:STN:280: DC%2BD3s3mvFGmsQ%3D%3D (Pubitemid 36827209)
24. J Baselga D Rischin M Ranson H Calvert E Raymond DG Kieback SB Kaye L Gianni A Harris T Bjork SD Averbuch A Feyereislova H Swaisland F Rojo J Albanell 2002 Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839: a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 4292 4302 12409327 10.1200/JCO.2002.03.100 1:CAS:528:DC%2BD38Xpt1CjtLo%3D (Pubitemid 35266289)
25. RS Herbst A-M Maddox ML Rothenberg EJ Small EH Rubin J Baselga F Rojo WK Hong H Swaisland SD Averbuch J Ochs P Mucci LoRusso 2002 Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial J Clin Oncol 20 3815 3825 12228201 10.1200/JCO.2002.03.038 1:CAS:528:DC%2BD38XntVyns7s%3D
26. M Ranson LA Hammond D Ferry M Kris A Tullo PI Murray V Miller S Averbuch J Ochs C Morris A Feyereislova H Swaisland EK Rowinsky 2002 ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 2240 2250 11980995 10.1200/JCO.2002.10.112 1:CAS:528:DC%2BD38XktVKrsrc%3D (Pubitemid 34441651)
27. H Patel MJ Egorin SC Remick D Mulkerin CHM Takimoto JH Doroshow D Potter SP Ivy AJ Murgo RK Ramanathan 2004 Comparison of Child-Pugh criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing J Clin Oncol ASCO Ann Meet Proc (Post-Meeting Edition) 22 6051
28. A Grieco R Castellano A Matera S Marcoccia P Di Rocco E Ragazzoni FM Vecchio G Gasbarrini 1998 Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients J Gastroenterol Hepatol 13 460 466 9641640 10.1111/j.1440-1746.1998.tb00668.x 1:CAS:528:DyaK1cXktVCjt7s%3D (Pubitemid 28258943)
29. JG Maring H Piersma A van Dalen HJ Groen DR Uges EG De Vries 2003 Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics Cancer Chemother Pharmacol 51 167 173 12647019 1:CAS:528:DC%2BD3sXit1Sgsr8%3D (Pubitemid 36259478)
30. G Koren K Beatty A Seto TR Einarson M Lishner 1992 The effects of impaired liver function on the elimination of antineoplastic agents Ann Pharmacother 26 363 371 1554959 1:CAS:528:DyaK38Xit1Ont78%3D
31. NA Dobbs CJ Twelves W Gregory C Cruickshanka MA Richards RD Rubens 2003 Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme Eur J Cancer 39 580 586 12628836 10.1016/S0959-8049(02)00669-X 1:CAS:528:DC%2BD3sXhvFGkurg%3D (Pubitemid 36287369)
32. WS Siegel-Lakhai M Crul P De Porre S Zhang I Chang H Boot JH Beijnen JHM Schellens 2006 Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function J Clin Oncol 24 4558 4564 17008695 10.1200/JCO.2006.05.8123 1:CAS:528:DC%2BD28XhtFemtrbJ (Pubitemid 46630951)
33. CW Shephard L Finelli MJ Alter 2005 Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 558 567 10.1016/S1473-3099(05)70216-4 (Pubitemid 41196755)